RxDoctor Payments Data

Christopher Merrick, MD

Pulmonary Disease · Colorado Springs, CONPI 1942566419

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Stryker at 40.0% of the total. 2025 is the largest year on record at $29,760, more than ten times the $676 reported in 2019.

$33,631in general payments, 2019–2025

Across 306 payments — averaging $109.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$13K
  • Electromed, Inc.$11K
  • Sanofi$3K
  • Insmed, Inc.$2K
  • AstraZeneca$1K
  • Inari Medical, Inc.$708
  • plus $3K from 34 others
$115,285in research payments, 2019–2025

Across 1 payment — averaging $115,285 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$115K

What the payments were for

  • Consulting fees$14,12042%
  • Travel & lodging$3,32110%
  • Food & beverage$16,09048%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,631 in reported general payments places this provider in the 85th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$138,967
Medicare patients
492
Services billed
1,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter166$185,501
ZemairaAlpha-1-Proteinase Inhibitor13$117,079
TezspireTezepelumab-Ekko13$57,105
Pirfenidone27$57,063
Spiriva RespimatTiotropium Bromide26$18,441
Spiriva HandihalerTiotropium Bromide24$17,393
Breo ElliptaFluticasone/Vilanterol14$15,044
SymbicortBudesonide/Formoterol Fumarate30$14,137
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,850
Albuterol Sulfate HfaAlbuterol Sulfate121$4,665
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,389
Wixela InhubFluticasone Propion/Salmeterol12$2,331
Advair DiskusFluticasone Propion/Salmeterol11$2,173
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,085
Pantoprazole Sodium31$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$567$204,934192 claims
AstraZenecaTezspire, Symbicort, Breztri Aerosphere$1,402$83,09254 claims
Boehringer IngelheimSpiriva Respimat$105$18,44126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →